Cencora Agrees to Take Controlling Stake in American Oncology Network in $2.4 Billion Deal Spanning 21 States
Cencora agreed to acquire American Oncology Network (AON) for $2.4 billion, expanding its oncology services. The deal, pending approval, includes $2.3 billion at closing plus up to $100 million in contingent value rights. Cencora already owns 4% of AON and aims to increase its stake to 75%. The acquisition is part of a broader trend of drug wholesalers buying cancer practice management companies.
How this was made
The 30-second read
Why it matters
The $2.4 billion acquisition of AON adds ~350 oncology providers, potentially increasing Cencora's drug distribution volumes and data assets.
Market read
First‑report M&A news with a multi‑billion dollar valuation that could move Cencora's stock and affect the broader healthcare distribution sector.
What to watch
Regulatory clearance and AON shareholder approval are still pending; any delay could dampen the anticipated upside.
Background
Cencora, formerly AmerisourceBergen, is expanding its oncology management services platform after previously acquiring a stake in OneOncology.
Market effects
Strengthens consolidation trend in the oncology services sector, pressuring peers such as Cardinal Health and McKesson.
May boost US healthcare distribution stocks as the deal expands Cencora's footprint across 21 states.
Highlights growing interest of drug distributors in owning oncology practice networks, a theme relevant to global pharma supply chains.
Counterpoint
If integration challenges arise, the deal could strain Cencora's margins and lead to a pull‑back in the stock.
Key entities
- CompanyCencora
US‑listed drug distributor (ticker CNC) executing the acquisition.
- CompanyAmerican Oncology Network
Private physician‑led oncology network being acquired.


